Makers Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Signal Improved Price Attractiveness

As of 23 June 2026, Makers Laboratories Ltd trades at a price of ₹147.80, down 2.09% from the previous close of ₹150.95. The stock’s 52-week range spans from ₹109.00 to ₹186.70, indicating a moderate recovery from its lows but still below its peak levels. The company’s micro-cap status and recent valuation grade upgrade from Sell to Hold on 22 June 2026 underscore a cautious but improving outlook.

Key valuation ratios reveal the stock’s newfound appeal. The price-to-earnings (P/E) ratio stands at 37.11, which, while elevated, is now considered attractive relative to its historical range and peer group. The price-to-book value (P/BV) ratio is 1.20, signalling that the stock is trading close to its book value, a factor that often appeals to value-oriented investors. Enterprise value to EBITDA (EV/EBITDA) is 5.51, a figure that is notably lower than many peers, suggesting the stock is undervalued on an operational earnings basis.

Comparative Peer Analysis Highlights Relative Value

When compared with other companies in the Pharmaceuticals & Biotechnology sector, Makers Laboratories Ltd’s valuation stands out favourably. For instance, Bliss GVS Pharma and Kwality Pharma are rated as very expensive with P/E ratios of 38.42 and 36.83 respectively, and EV/EBITDA multiples of 29.71 and 22.24. Similarly, NGL Fine Chem and Shukra Pharma trade at even higher multiples, with P/E ratios exceeding 40 and EV/EBITDA multiples above 27.

In contrast, Makers Labs’ EV/EBITDA of 5.51 is significantly lower, indicating a more reasonable valuation relative to earnings before interest, taxes, depreciation and amortisation. This disparity suggests that the market may be underestimating the company’s operational efficiency or growth prospects compared to its peers.

Other peers such as Venus Remedies and Fredun Pharma have fair to attractive valuations but still trade at higher EV/EBITDA multiples of 14.77 and 16.66 respectively. This further emphasises Makers Laboratories’ relative undervaluation within the sector.

Financial Performance and Returns Contextualise Valuation

Makers Laboratories’ return on capital employed (ROCE) is a healthy 15.26%, indicating efficient use of capital to generate profits. However, the return on equity (ROE) is modest at 3.22%, reflecting limited profitability relative to shareholder equity. This disparity may explain some investor caution despite the attractive valuation.

Examining stock returns relative to the Sensex reveals mixed performance. Over the year-to-date (YTD) period, Makers Labs has delivered a robust 25.10% return, outperforming the Sensex’s negative 9.54%. Over three years, the stock has gained 33.21%, also ahead of the Sensex’s 21.91%. However, longer-term returns over five and ten years lag the benchmark, with a 5-year loss of 26.14% versus a 46.60% gain for the Sensex, and a 10-year gain of 132.76% compared to Sensex’s 188.03%.

This performance profile suggests that while the company has recently regained investor favour, it faces challenges in sustaining long-term growth and market leadership.

Sector and Market Dynamics Influence Valuation Shifts

The Pharmaceuticals & Biotechnology sector remains competitive and capital intensive, with many companies trading at elevated multiples due to growth expectations and innovation potential. Makers Laboratories’ micro-cap status and relatively conservative financial metrics have historically limited its valuation premium.

Recent valuation grade improvement from Sell to Hold and a Mojo Score of 50.0 reflect a cautious upgrade in sentiment. The company’s valuation grade has shifted from fair to attractive, signalling that investors now perceive better value in the stock relative to its fundamentals and sector peers.

Nonetheless, the stock’s 1-month return of -10.02% versus Sensex’s 2.23% gain highlights near-term volatility and investor uncertainty. The recent price decline may have contributed to the improved valuation attractiveness, presenting a potential entry point for value-focused investors.

Investment Implications and Outlook

For investors analysing Makers Laboratories Ltd, the shift to an attractive valuation grade offers a compelling reason to reassess the stock’s potential. The relatively low EV/EBITDA multiple of 5.51 compared to sector heavyweights suggests undervaluation on operational earnings. Meanwhile, the P/E ratio of 37.11, though elevated, is justified by recent outperformance and improved capital efficiency.

However, the modest ROE and recent price volatility caution against overenthusiasm. The company’s micro-cap status entails liquidity risks and greater sensitivity to market swings. Investors should weigh these factors alongside the stock’s valuation appeal.

Comparative analysis with peers reveals that Makers Laboratories is positioned attractively within a sector where many companies trade at stretched multiples. This relative value could attract institutional interest if accompanied by consistent earnings growth and margin expansion.

In summary, Makers Laboratories Ltd’s valuation parameters have improved materially, reflecting a more favourable price entry point amid sector challenges. While risks remain, the stock’s repositioning from fair to attractive valuation grade and upgraded Mojo Grade to Hold mark a positive development for investors seeking exposure to the Pharmaceuticals & Biotechnology micro-cap space.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →